Close Menu

NEW YORK (360Dx) – Bio-Rad Laboratories today announced 510(k) clearance and CE marking for an updated version of the Liquichek Tumor Marker Control.

The updated control has four new analytes and is being launched for the immunoassay-based tumor marker testing market. The control now features HE4 and HER-2neu. The two other new analytes, proGRP and SCC, are available only outside of the US.

The control also offers low levels of prostate-specific antigen, high levels of cancer antigens, and ferritin.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.